Evidence map›Paper›PMID 41009512›Full record

ArticleInternational journal of molecular sciences2025

Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer.

Burak İlhan, Sibel Kuraş, Berkay Kılıç, Ceren Tilgen Yasasever, Hilal Oğuz Soydinç, Hani Alsaadoni, Gözde Öztan, Arash Adamnejad Ghafour, Muhammed Ucuncu, Enver Kunduz and 1 more

Erratum issuedAbstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Burak İlhanDepartment of Surgery, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-7538-7399
Sibel KuraşDepartment of Medical Biochemistry, Hamidiye Faculty of Medicine, University of Health Sciences, 34668 Istanbul, Türkiye.ORCID 0000-0002-1230-7777
Berkay KılıçDepartment of Surgery, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-9050-7571
Ceren Tilgen YasaseverDepartment of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-8732-4117
Hilal Oğuz SoydinçDepartment of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-7858-1584
Hani AlsaadoniDepartment of Medical Biology, International School of Medicine, University of Health Sciences, 34668 Istanbul, Türkiye.
Gözde ÖztanDepartment of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-2970-1834
Arash Adamnejad GhafourDepartment of Cancer Genetics, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.ORCID 0000-0002-4446-7783
Muhammed UcuncuDepartment of Anesthesia, Vocational School of Health Services, Istanbul Gelisim University, 34310 Istanbul, Türkiye.ORCID 0000-0003-4638-1059
Enver KunduzDepartment of Surgery, Faculty of Medicine, Bezmialem Foundation University, 34093 Istanbul, Türkiye.
Süleyman BademlerDepartment of Surgery, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of breast cancer (BC) remains a challenge despite advances in screening, leading to poor prognosis in late-stage disease. Circulating microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for early diagnosis. The study aimed to evaluate the diagnostic utility of serum miR-197-3p, miR-1236, and miR-1271 levels in distinguishing BC patients from healthy individuals. Serum samples from 92 BC patients and 31 healthy controls were analyzed. Total RNA was extracted, and miRNA expression levels were quantified using quantitative real-time PCR (qRT-PCR). Expression differences were assessed using the ΔCt method. Receiver Operating Characteristic (ROC) curve analysis evaluated diagnostic performance. Serum miR-197-3p levels were significantly upregulated (fold change = 8.939,

Indexed as

Biomarkers, TumorBreast NeoplasmsMicroRNAsAdultAgedCase-Control StudiesEarly Detection of CancerFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedROC CurveBiomarkers, TumorMicroRNAsMIRN197 microRNA, humanbiomarkerbreast cancercirculating miRNAearly diagnosisliquid biopsymicroRNAqRT-PCR

Identifiers

PMID41009512
PMCPMC12469449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.